05:20 PM EDT, 03/11/2024 (MT Newswires) -- Larimar Therapeutics ( LRMR ) said Monday it dosed the first patient in its open-label extension study of 25 milligrams daily injection of nomlabofusp in patients with Friedreich's ataxia, neurodegenerative movement disorder.

The company said the study will inform about the long-term safety profile of the drug and frataxin protein levels in tissue, which is essential mitochondrial function.

Participants from the prior phase 1 and phase 2 studies of the drug are eligible to screen for the open-label extension study, Larimar added.

The company expects to announce initial data in Q4 and file a potential biologics license application, for accelerated approval in H2 2025.

Larimar shares were up 2% in recent after hours activity.

Price: 8.84, Change: +0.21, Percent Change: +2.43